Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Finance
1



[
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
[og_img]
https://www.investing.com/news/press-releases/sutro-biopharma-presents-data-from-doseoptimization-portion-of-refrimeo1-trial-in-patients-with-platinum-resistant-ovarian-cancer-at-sgo-2025-93CH-3930796


Investing.com

Montather Rassoul
Montather Rassoulhttps://thefifthskill.com/

Latest articles

spot_imgspot_img
Previous article
ROSEN, A TOP RANKED LAW FIRM, Encourages Polestar Automotive Holding UK PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – PSNY
Next article
ROSEN, A TOP RANKED LAW FIRM, Encourages Newmont Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEM

Related articles

Leave a reply

Please enter your comment!
Please enter your name here

spot_imgspot_img

Popular articles

Featured

Newsletter

Subscribe to get the latest news, offers and special announcements.

By subscribing, you're accepting to receive promotions.

© Copyright - Newspaper WordPress Theme by TagDiv